Clinical Trial Update: Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma [NA]

View source ↗

Summary

A clinical trial update describes a fixed-duration regimen of zanubrutinib, bendamustine, and obinutuzumab (ZBG) as first-line therapy for treatment-naive advan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Obinutuzumab (obinutuzumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Follicular Lymphoma, Treatment Naive | NA | Status: RECRUITING